Visceral leishmaniasis associated with human immunodeficiency virus infection;Leishmaniasis visceral asociada a la infección por el virus de la inmunodeficiencia humana

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 19, Issue 7, 2001, Pages 353-357

  Pintado, V ^a   Lopez Velez R ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ANTIRETROVIRUS AGENT; GAMMA INTERFERON;

CHEMICAL ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; LIVER BIOPSY; NOTE; VISCERAL LEISHMANIASIS;

EID: 0034791593     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(01)72665-1     Document Type: Note

References (42)

1. HIV-associated visceral leishmaniasis
2. Leishmania and human immunodeficiency virus coinfection: The first 10 years
3. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: A comparative study
4. Clinico-epidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain
5. Leishmania/HIV co-infection, south-western Europe, 1990-1998. Retrospective analysis of 965 cases
6. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases
7. Características clínicas y evolutivas de la leishmaniasis visceral en pacientes con infección por VIH
8. Visceral leishmaniasis in HIV-1-infected individuals: A common opportunistic infection in Spain?
9. Leishmaniasis visceral: Estudio comparativo de pacientes con y sin infección por el virus de la inmunodeficiencia humana
10. Visceral leishmaniasis in patients infected with the human immunodeficiency virus
11. Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART)
12. Highly active antiretroviral therapy decreases in the incidence of visceral leishmaniasis in HIV-infected individuals
13. Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy
14. Infuence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients
15. AIDS and Leishmania infantum. New approaches for a new epidemiological problem
16. Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS
17. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV)
18. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani
19. HIV-Leishmania co-infection in Italy: Serological data as an indication of the sequence of acquisition of the two infections
20. Visceral leishmaniasis in HIV-positive patients: Primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts
21. HIV and Leishmania coinfection: A review of 91 cases with focus on atypical locations of Leishmania
22. Visceral leishmaniasis and HIV-1 co-infection in southern France
23. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients
24. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture and serology for diagnosis of visceral leishmaniasis in immunocompromised patients
25. Treatment of Mediterranean visceral leishmaniasis
26. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV
27. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
28. Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)
29. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus
30. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B
31. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: Report of two cases
32. Amphotericin B lipid complex vs meglumine antimoniate in the treatment of visceral leishmaniasis in HIV-infected patients: A multicenter, open-label with blinded centralized randomisation and parallel clinical trial
33. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients
34. Leishmania and HIV infection: A collaborative study of 228 cases in a Spanish Mediterranean area
35. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients
36. Discontinuation of anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy
37. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy
38. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of the highly active antiretroviral therapy
39. Leishmaniasis visceral en pacientes con infección por VIH
40. Prolonged survival after highly active antiretroviral therapy (HAART) in AIDS-associated visceral leishmaniasis
41. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults